|
Aug 6
|
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
|
|
Aug 5
|
Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update
|
|
Jul 31
|
Viridian and Kissei to advance veligrotug and VRDN-003 in Japan
|
|
Jul 30
|
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments
|